SCHEMBL208333

SCHEMBL208333

C1=NC2=CNCNC2=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30930198 0.56
SCHEMBL12542798 0.55
SCHEMBL32667916 0.54
SCHEMBL3384236 0.54
SCHEMBL23217936 0.53
SCHEMBL18536827 0.52
SCHEMBL16274374 0.52
SCHEMBL28873585 0.52
SCHEMBL19892423 0.52
SCHEMBL18120815 0.52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421238-B2 Selective dihydropyrrolopyrimidine JAK2 inhibitors CHENGDU JINRUI FOUNDATION BIOTECH CO., LTD. (CN) 2025-09-23 US claimed
US-12005127-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2024-06-11 US claimed
EP-3740480-B1 DNA-PK INHIBITORS VERTEX PHARMA (US) 2024-03-06 EP claimed
US-11813267-B2 DNA-PK inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-11-14 US claimed
EP-3985003-B1 DNA-PK INHIBITORS VERTEX PHARMA (US) 2023-08-09 EP claimed
US-20220235064-A1 OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME WELLMARKER BIO CO., LTD. (KR) 2022-07-28 US claimed
EP-4011885-A1 OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Wellmarker Bio Co., Ltd. (KR) 2022-06-15 EP claimed
EP-4006031-A1 DIHYDRO-PYRROLO-PYRIMIDINE SELECTIVE JAK2 INHIBITOR Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) 2022-06-01 EP claimed
US-20220144844-A1 SELECTIVE DIHYDROPYRROLOPYRIMIDINE JAK2 INHIBITORS Shanghai Xunhe Pharmaceutical Technology Co. Ltd. (CN) 2022-05-12 US claimed
EP-3985003-A1 DNA-PK INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2022-04-20 EP claimed
EP-1551341-A2 USE OF Y-27632 AS AN AGENT TO PREVENT RESTENOSIS AFTER CORONARY ARTERY ANGIOPLASTY/STENT IMPLANTATION The Trustees of Columbia University in the City of New York (US) 2005-07-13 EP claimed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US claimed
WO-2005011601-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS, INC. (US) 2005-02-10 WO claimed
US-20040028716-A1 Use of Y-27632 as an agent to prevent restenosis after coronary artery angioplasty/stent implantation TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE 2004-02-12 US claimed
WO-2003105923-A2 USE OF Y-27632 AS AN AGENT TO PREVENT RESTENOSIS AFTER CORONARY ARTERY ANGIOPLASTY/STENT IMPLANTATION THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OFNEW YORK (US) 2003-12-24 WO claimed
US-6451825-B1 FOR THERAPY OF HYPERTENSION, A THERAPEUTIC AGENT OF ANGINA PECTORIS, A SUPPRESSIVE AGENT OF CEREBROVASCULAR CONTRACTION, ASTHMA, PERIPHERAL CIRCULATION DISORDER, AS PROPHYLACTIC AGENT OF IMMATURE BIRTH, A THERAPEUTIC AGENT OF ARTERIOSCLEROSIS MITSUBISHI PHARMA CORPORATION (JP) 2002-09-17 US claimed
EP-1195372-A1 N-heterocyclic substituted benzamide derivatives with antihypertensive activity Mitsubishi Pharma Corporation (JP) 2002-04-10 EP claimed
US-6218410-B1 ADMINISTERING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF A RHO KINASE INHIBITOR COMPRISING AMIDE COMPOUND FOR INHIBITING RHO KINASE YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2001-04-17 US claimed
US-6156766-A Benzamide compounds and pharmaceutical use thereof YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-12-05 US claimed
US-4272606-A HYDRAZIDE, THIOAMIDE FUJI PHOTO FILM CO., LTD. (JP) 1981-06-09 US claimed